What is Wedbush’s Forecast for ORKA FY2024 Earnings?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Stock analysts at Wedbush decreased their FY2024 earnings estimates for shares of Oruka Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($2.46) per share for the year, down from their previous estimate of ($0.99). Wedbush has a “Outperform” rating and a $40.00 price target on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($2.50) per share. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.36) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($2.08) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($2.94) EPS.

Several other research analysts have also recently weighed in on the stock. Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. TD Cowen began coverage on Oruka Therapeutics in a research report on Monday, September 16th. They issued a “buy” rating for the company. Jefferies Financial Group began coverage on Oruka Therapeutics in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price target on the stock. Leerink Partners began coverage on Oruka Therapeutics in a report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price target for the company. Finally, Stifel Nicolaus started coverage on shares of Oruka Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $49.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $43.17.

Oruka Therapeutics Stock Up 5.5 %

ORKA stock opened at $22.30 on Monday. Oruka Therapeutics has a 1 year low of $18.72 and a 1 year high of $53.88. The stock has a market capitalization of $26.98 million, a price-to-earnings ratio of -3.48 and a beta of 0.87. The firm has a 50 day moving average of $26.62.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC purchased a new position in Oruka Therapeutics during the third quarter worth about $343,000. Frazier Life Sciences Management L.P. purchased a new stake in Oruka Therapeutics in the 3rd quarter valued at approximately $11,699,000. Wellington Management Group LLP purchased a new stake in shares of Oruka Therapeutics in the third quarter valued at $2,013,000. RTW Investments LP acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $45,359,000. Finally, Redmile Group LLC acquired a new stake in Oruka Therapeutics during the third quarter worth approximately $10,091,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.